48
Participants
Start Date
April 19, 2021
Primary Completion Date
October 31, 2024
Study Completion Date
December 31, 2025
RP72
RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
Gemcitabine
Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
RECRUITING
Chi Mei Hospital, Liouying, Tainan City
RECRUITING
National Cheng Kung University Hospital, Tainan City
T-TOP Clinical Research Co., Ltd.
INDUSTRY
Rise Biopharmaceuticals, Inc.
INDUSTRY